Early non-responders in teriparatide therapy: retrospective analysis
Authors:
Masaryk Pavol; Letkovská Alexandra
Authors‘ workplace:
Národný ústav reumatických chorôb, Piešťany
Published in:
Clinical Osteology 2020; 25(1): 45-49
Category:
Overview
Teriparatide (TPTD) is a potent osteoanabolic drug. A potential drawback associated with teriparatide treatment is a failure of effect. The incidence of non-responders depends on the definition of lack of response to treatment, baseline bone density, duration of treatment, prior antiresorptive therapy, and measurement accuracy. In our study, we analyzed “early non-responders” after 6 and 12 months of treatment in a group of 306 patients. We identified 36 (11.7 %) patients as early non-responders, of whom 18 after 6 months of treatment and 18 after one year of treatment. There were only 4 men and up to 32 women in the sample, but the percentage of non-responders among the sexes was approximately the same (men: 10.5 %, women: 11.9 %). Early non-responders in glucocorticoid osteoporosis were significantly more represented. Previous antiresorptive therapy, especially bisphosphonates, increased the risk of a lack of response to teriparatide therapy.
Keywords:
teriparatide – non-responders
Sources
Eriksen EF, Keaveny TM, Gallagher ER et al. Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 2014; 67: 246–256. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2014.07.014>.
Dempster DW, Cosman F, Parisien M et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14(6): 690–709. Dostupné z DOI: <http://dx.doi.org/10.1210/edrv-14–6-690>.
Body JJ, Gaich GA, Scheele WH et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2000; 87(10): 4528–4535. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2002–020334>.
Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434–1441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200105103441904>.
Gallagher JC, Rosen CJ, Chen P et al. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 2006; 39(6): 1268–1275. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2006.06.007>.
Heaney RP, Watson P. Variability in the measured response of bone to teriparatide. Osteoporos Int 2011; 22(6): 1703–1708. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–010–1376–1>.
Elraiyah T, Ahmed AH, Wang Z et al. Predictors of teriparatide treatment failure in patients with low bone mass. Bone Reports 2016; 4: 17–22. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bonr.2015.11.001>.
Payer J, Tomková S, Jackuliak P et al. Teriparatid v liečbe ťažkej osteoporózy u starších pacientok: výsledky multicentrickej prospektívnej štúdie. Clin Osteol 2018; 23(3): 88–93.
Payer J, Tomková S, Killinger Z et al. 18-mesačná liečba teriparatidom zlepšuje u pacientov s glukokortikoidmi indukovanou osteoporózou hodnoty hustoty kostného minerálu a trabekulárne kostné skóre: výsledky prospektívneho sledovania (register OSTEO.sk). Clin Osteol 2018; 23(4): 138–145.
Minne H, Audran M, Maria E et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 2008; 24(11): 3117–3128. Dostupné z DOI: <http://dx.doi.org/10.1185/03007990802466595>.
Niimi R, Kono T, Nishihara TA et al. A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int 2016; 27(9): 2845–2853. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–016–3581-z>. Erratum in Erratum to: A retrospective analysis of nonresponse to daily teriparatide treatment.
Niimi R, Kono T, Nishihara A et al. Osteoporos Int 2016; 27(9): 2887–2888. Dostupné z DOI: <http://dx.doi.oerg/10.1007/s00198–016–3625–4>.
Kim SY, Zhang M, Bockman R. Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis. HSSJ 2017; 13(2): 171–177. Dostupné z DOI: <http://dx.doi.org/10.1007/s11420–016–9537–1>.
Cohen A, Stein EM, Recker RR et al. Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study. J Clin Endocrinol Metab 2013; 98(5): 1971–1981. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–1172>.
Ettinger B, San Martin J, Crans G et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19(5): 745–751. Dostupné z DOI: <http://dx.doi.org/10.1359/JBMR.040117>.
Lindsay R, Zhou H, Cosman F et al. Effects of a one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007; 22(4): 495–502. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.070104>.
Borggrefe J, Graeff C, Nickelsen T N el al. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 2010; 25(3): 472–481. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.090820>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyArticle was published in
Clinical Osteology
2020 Issue 1
Most read in this issue
- Atypical cases of secondary hyperparathyroidism in patients with kidney disease and failure: case reports
- Guidelines for osteoporotic patients during COVID-19 pandemics
- Effect of anorexia nervosa on bone metabolism
- Management of osteoporosis and calcium metabolism disorders during COVID-19 pandemics